Hoshida S, Kuzuya T, Yamashita N, Nishida M, Kitahara S, Hori M, Kamada T, Tada M
First Department of Medicine, Osaka University School of Medicine, Suita, Japan.
J Am Coll Cardiol. 1994 Nov 1;24(5):1391-7. doi: 10.1016/0735-1097(94)90125-2.
The aim of this study was to examine the infarct-limiting effects of gamma-glutamylcysteine ethyl ester, a newly discovered synthetic precursor of glutathione biosynthesis, in a canine model of myocardial infarction.
Reduced glutathione plays an important role in protecting cells against damage induced by reactive oxygen species during myocardial ischemia and reperfusion. Gamma-glutamylcysteine ethyl ester is capable of penetrating into cells in its intact form and increasing intracellular glutathione levels.
Dogs were subjected to a 90-min coronary occlusion followed by 5 h of reperfusion. An intravenous bolus injection of gamma-glutamylcysteine ethyl ester (3 or 10 mg/kg body weight) was administered immediately before reperfusion. Regional myocardial blood flow was measured with the use of colored microspheres.
Gamma-glutamylcysteine ethyl ester effectively reduced infarct size in a dose-dependent manner (mean +/- SEM 26.4 +/- 3.5% in the low dose group [3 mg/kg, n = 10] and 19.0 +/- 3.4% in the high dose group [10 mg/kg, n = 10]; each p < 0.05 vs. the value in the control group [40.6 +/- 4.8%, n = 10]). There were no differences between the control and treated groups in hemodynamic variables or regional myocardial blood flow either during the ischemic period or after reperfusion. The reduced glutathione content of ischemic myocardium in the control group (0.62 +/- 0.11 mumol/g, p < 0.01) was significantly lower than that in nonischemic myocardium (1.46 +/- 0.07 mumol/g), and it was preserved by treatment in a dose-dependent manner (3 mg/kg, 0.83 +/- 0.06 mumol/g; 10 mg/kg, 0.92 +/- 0.14 mumol/g; each p < 0.05 vs. control level). There were no differences in oxidized glutathione content between nonischemic and ischemic myocardium or among the three groups.
Gamma-glutamylcysteine ethyl ester, a precursor of glutathione, significantly attenuates myocardial ischemia and reperfusion injury when administered immediately before reperfusion.
本研究旨在检测γ-谷氨酰半胱氨酸乙酯(一种新发现的谷胱甘肽生物合成的合成前体)在犬心肌梗死模型中的梗死限制作用。
还原型谷胱甘肽在心肌缺血和再灌注期间保护细胞免受活性氧诱导的损伤中起重要作用。γ-谷氨酰半胱氨酸乙酯能够以完整形式穿透细胞并增加细胞内谷胱甘肽水平。
对犬进行90分钟的冠状动脉闭塞,随后再灌注5小时。在再灌注前立即静脉推注γ-谷氨酰半胱氨酸乙酯(3或10毫克/千克体重)。使用彩色微球测量局部心肌血流量。
γ-谷氨酰半胱氨酸乙酯以剂量依赖性方式有效减小梗死面积(低剂量组[3毫克/千克,n = 10]平均±标准误为26.4±3.5%,高剂量组[10毫克/千克,n = 10]为19.0±3.4%;与对照组[40.6±4.8%,n = 10]的值相比,每组p < 0.05)。在缺血期或再灌注后,对照组和治疗组在血流动力学变量或局部心肌血流量方面无差异。对照组缺血心肌的还原型谷胱甘肽含量(0.62±0.11微摩尔/克,p < 0.01)显著低于非缺血心肌(1.46±0.07微摩尔/克),并且通过治疗以剂量依赖性方式得以保留(3毫克/千克,0.83±0.06微摩尔/克;10毫克/千克,0.92±0.14微摩尔/克;与对照水平相比,每组p < 0.05)。非缺血心肌和缺血心肌之间或三组之间氧化型谷胱甘肽含量无差异。
谷胱甘肽前体γ-谷氨酰半胱氨酸乙酯在再灌注前立即给药时可显著减轻心肌缺血和再灌注损伤。